[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f1KqbmGS3fDySky0AQT7hfNa-G-t3Ea0tH_bWzJ4U7DI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"Second Affiliated Hospital of Guangzhou Medical University",[4],71,false,43,11,16362,17,[13,16,19,21,24,27,30,33],{"name":14,"count":15},"Hepatocellular Carcinoma Non-resectable",16,{"name":17,"count":18},"Solid Tumor, Adult",10,{"name":20,"count":18},"Lung Cancer",{"name":22,"count":23},"Hepatocellular Carcinoma",9,{"name":25,"count":26},"Liver Cancer",6,{"name":28,"count":29},"Pancreas Cancer",4,{"name":31,"count":32},"Breast Cancer",3,{"name":34,"count":32},"Surgery",[36,41,46,51,56,61,65,70,75,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05992584","Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC","2026-01-09","Lenvatinib, sintilimab plus SIRT",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT07374328","Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus","2026-05-31","Semaglutide",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06492395","Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT","2026-07-31","Len+DEB-TACE+HAIC",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT03198052","GPC3\u002FMesothelin\u002FClaudin18.2\u002FGUCY2C\u002FB7-H3\u002FPSCA\u002FPSMA\u002FMUC1\u002FTGFβ\u002FHER2\u002FLewis-Y\u002FAXL\u002FEGFR-CAR-T Cells Against Cancers","2026-08-01","CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05608213","Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC","2026-10-31","Lenvatinib",{"nctId":62,"briefTitle":63,"date":59,"intervention":64},"NCT05608200","Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC","Lenvatinib, sintilimab plus TACE",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT03769129","Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC","2026-11-01","Pembrolizumab",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05882708","Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis","2026-12-31","Ivabradine",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06966830","Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus","2027-04-30","Lacosamide",{"nctId":81,"briefTitle":82,"date":78,"intervention":83},"NCT06397235","DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC","DEB-TACE+HAIC",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,119,152,177,195,221,252,272,290,312,333,351,387,417,440,458,483,501,525,543,565,583,605,630,651,676,699,728,751,777,802,825,853,877,903,926,951,977,1000,1026,1050,1068,1094,1116,1142,1160,1186,1204,1228,1251,1275,1301,1319,1343,1369,1392,1414,1439,1461,1485,1510,1528,1552],{"intervention":74,"totalTrials":93,"cells":94},1,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":117},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":97},[],{"trials":105,"activeCount":93,"soonestReadout":73},[106],{"nctId":71,"briefTitle":72,"status":107,"phases":108,"primaryCompletion":73,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":116},"RECRUITING",[89],"2027-05-31","2023-06-01",172,[113,74,114,115],"Sepsis","Hemodynamics","Heart Rate Control",[74],{"trials":118,"activeCount":97},[],{"intervention":60,"totalTrials":120,"cells":121},2,{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":139,"PHASE4":148,"NA":150},{"trials":123,"activeCount":97},[],{"trials":125,"activeCount":97},[],{"trials":127,"activeCount":93,"soonestReadout":132},[128],{"nctId":129,"briefTitle":130,"status":107,"phases":131,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":137},"NCT06904196","Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC",[87],"2028-03-31","2029-03-31","2025-04-01",78,[14],[138,60],"Lenvatinib plus SIRT",{"trials":140,"activeCount":93,"soonestReadout":59},[141],{"nctId":57,"briefTitle":58,"status":107,"phases":142,"primaryCompletion":59,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":147},[88],"2026-12-01","2022-11-02",187,[14],[60],{"trials":149,"activeCount":97},[],{"trials":151,"activeCount":97},[],{"intervention":153,"totalTrials":93,"cells":154},"Sin-Bev-TACE",{"EARLY_PHASE1":155,"PHASE1":157,"PHASE2":159,"PHASE3":161,"PHASE4":173,"NA":175},{"trials":156,"activeCount":97},[],{"trials":158,"activeCount":97},[],{"trials":160,"activeCount":97},[],{"trials":162,"activeCount":93,"soonestReadout":167},[163],{"nctId":164,"briefTitle":165,"status":107,"phases":166,"primaryCompletion":167,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":171},"NCT05985798","Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC",[88],"2027-07-31","2023-08-01",258,[14],[153,172],"Len-TACE",{"trials":174,"activeCount":97},[],{"trials":176,"activeCount":97},[],{"intervention":172,"totalTrials":93,"cells":178},{"EARLY_PHASE1":179,"PHASE1":181,"PHASE2":183,"PHASE3":185,"PHASE4":191,"NA":193},{"trials":180,"activeCount":97},[],{"trials":182,"activeCount":97},[],{"trials":184,"activeCount":97},[],{"trials":186,"activeCount":93,"soonestReadout":167},[187],{"nctId":164,"briefTitle":165,"status":107,"phases":188,"primaryCompletion":167,"completion":167,"start":168,"enrollment":169,"conditions":189,"interventions":190},[88],[14],[153,172],{"trials":192,"activeCount":97},[],{"trials":194,"activeCount":97},[],{"intervention":196,"totalTrials":93,"cells":197},"PD1\u002FPDL1\u002FCTLA4 inhibitors",{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":204,"PHASE4":217,"NA":219},{"trials":199,"activeCount":97},[],{"trials":201,"activeCount":97},[],{"trials":203,"activeCount":97},[],{"trials":205,"activeCount":93,"soonestReadout":210},[206],{"nctId":207,"briefTitle":208,"status":107,"phases":209,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":214,"interventions":216},"NCT03952065","IT or IA Infusion of PD1\u002FPDL1\u002FCTLA4 Inhibitors Versus IV for Immunotherapy of Head\u002FNeck Cancers (HNC)",[87,88],"2029-01-01","2035-01-01","2019-01-01",200,[215],"Head\u002FNeck Neoplasm",[196],{"trials":218,"activeCount":97},[],{"trials":220,"activeCount":97},[],{"intervention":222,"totalTrials":93,"cells":223},"Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy",{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":230,"PHASE4":248,"NA":250},{"trials":225,"activeCount":97},[],{"trials":227,"activeCount":97},[],{"trials":229,"activeCount":97},[],{"trials":231,"activeCount":93,"soonestReadout":236},[232],{"nctId":233,"briefTitle":234,"status":107,"phases":235,"primaryCompletion":236,"completion":237,"start":238,"enrollment":213,"conditions":239,"interventions":247},"NCT03755739","Trans-Artery\u002FIntra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors",[87,88],"2033-11-01","2036-11-01","2018-11-01",[240,20,241,242,243,28,244,245,246,31],"Hepatocarcinoma","Melanoma","Renal Cancer","Head and Neck Cancer","Ovarian Cancer","Colo-rectal Cancer","Cervical Cancer",[222],{"trials":249,"activeCount":97},[],{"trials":251,"activeCount":97},[],{"intervention":64,"totalTrials":93,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":268,"NA":270},{"trials":255,"activeCount":97},[],{"trials":257,"activeCount":97},[],{"trials":259,"activeCount":97},[],{"trials":261,"activeCount":93,"soonestReadout":59},[262],{"nctId":62,"briefTitle":63,"status":107,"phases":263,"primaryCompletion":59,"completion":59,"start":144,"enrollment":264,"conditions":265,"interventions":266},[88],427,[14],[64,267],"Lenvatinib plus TACE",{"trials":269,"activeCount":97},[],{"trials":271,"activeCount":97},[],{"intervention":267,"totalTrials":93,"cells":273},{"EARLY_PHASE1":274,"PHASE1":276,"PHASE2":278,"PHASE3":280,"PHASE4":286,"NA":288},{"trials":275,"activeCount":97},[],{"trials":277,"activeCount":97},[],{"trials":279,"activeCount":97},[],{"trials":281,"activeCount":93,"soonestReadout":59},[282],{"nctId":62,"briefTitle":63,"status":107,"phases":283,"primaryCompletion":59,"completion":59,"start":144,"enrollment":264,"conditions":284,"interventions":285},[88],[14],[64,267],{"trials":287,"activeCount":97},[],{"trials":289,"activeCount":97},[],{"intervention":291,"totalTrials":93,"cells":292},"PD1\u002FPDL1 inhibitor",{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":299,"PHASE4":308,"NA":310},{"trials":294,"activeCount":97},[],{"trials":296,"activeCount":97},[],{"trials":298,"activeCount":97},[],{"trials":300,"activeCount":93,"soonestReadout":210},[301],{"nctId":302,"briefTitle":303,"status":107,"phases":304,"primaryCompletion":210,"completion":305,"start":212,"enrollment":213,"conditions":306,"interventions":307},"NCT03949231","Infusion of PD1\u002FPDL1\u002FCTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma",[88],"2038-01-02",[25],[291],{"trials":309,"activeCount":97},[],{"trials":311,"activeCount":97},[],{"intervention":50,"totalTrials":93,"cells":313},{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":320,"PHASE4":329,"NA":331},{"trials":315,"activeCount":97},[],{"trials":317,"activeCount":97},[],{"trials":319,"activeCount":97},[],{"trials":321,"activeCount":93,"soonestReadout":49},[322],{"nctId":47,"briefTitle":48,"status":107,"phases":323,"primaryCompletion":49,"completion":167,"start":324,"enrollment":325,"conditions":326,"interventions":327},[88],"2024-08-01",178,[14],[50,328],"Len+DEB-TACE",{"trials":330,"activeCount":97},[],{"trials":332,"activeCount":97},[],{"intervention":328,"totalTrials":93,"cells":334},{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":347,"NA":349},{"trials":336,"activeCount":97},[],{"trials":338,"activeCount":97},[],{"trials":340,"activeCount":97},[],{"trials":342,"activeCount":93,"soonestReadout":49},[343],{"nctId":47,"briefTitle":48,"status":107,"phases":344,"primaryCompletion":49,"completion":167,"start":324,"enrollment":325,"conditions":345,"interventions":346},[88],[14],[50,328],{"trials":348,"activeCount":97},[],{"trials":350,"activeCount":97},[],{"intervention":352,"totalTrials":120,"cells":353},"ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab",{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":358,"PHASE3":381,"PHASE4":383,"NA":385},{"trials":355,"activeCount":97},[],{"trials":357,"activeCount":97},[],{"trials":359,"activeCount":120,"soonestReadout":375},[360,371],{"nctId":361,"briefTitle":362,"status":107,"phases":363,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":370},"NCT06482801","Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT",[87],"2030-12-30","2035-12-30","2024-06-10",90,[25,369],"Antibody",[352],{"nctId":372,"briefTitle":373,"status":107,"phases":374,"primaryCompletion":375,"completion":376,"start":377,"enrollment":367,"conditions":378,"interventions":380},"NCT06483347","Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT",[87],"2028-12-30","2033-12-30","2024-04-04",[20,379],"Inoperable Disease",[352],{"trials":382,"activeCount":97},[],{"trials":384,"activeCount":97},[],{"trials":386,"activeCount":97},[],{"intervention":388,"totalTrials":120,"cells":389},"ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab",{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":411,"PHASE4":413,"NA":415},{"trials":391,"activeCount":97},[],{"trials":393,"activeCount":97},[],{"trials":395,"activeCount":120,"soonestReadout":375},[396,404],{"nctId":397,"briefTitle":398,"status":107,"phases":399,"primaryCompletion":375,"completion":365,"start":400,"enrollment":367,"conditions":401,"interventions":403},"NCT06492421","Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.",[87],"2024-07-01",[20,34,402],"Non-small Cell Lung Cancer",[388],{"nctId":405,"briefTitle":406,"status":107,"phases":407,"primaryCompletion":375,"completion":376,"start":400,"enrollment":367,"conditions":408,"interventions":410},"NCT06492408","Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.",[87],[409,34],"Hepatic Cancer",[388],{"trials":412,"activeCount":97},[],{"trials":414,"activeCount":97},[],{"trials":416,"activeCount":97},[],{"intervention":45,"totalTrials":93,"cells":418},{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":434,"PHASE4":436,"NA":438},{"trials":420,"activeCount":97},[],{"trials":422,"activeCount":97},[],{"trials":424,"activeCount":93,"soonestReadout":44},[425],{"nctId":42,"briefTitle":43,"status":107,"phases":426,"primaryCompletion":44,"completion":427,"start":428,"enrollment":429,"conditions":430,"interventions":432},[86,87],"2026-08-31","2025-06-01",240,[431],"Type 2 Diabetes",[45,433],"Sitagliptin",{"trials":435,"activeCount":97},[],{"trials":437,"activeCount":97},[],{"trials":439,"activeCount":97},[],{"intervention":433,"totalTrials":93,"cells":441},{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":452,"PHASE4":454,"NA":456},{"trials":443,"activeCount":97},[],{"trials":445,"activeCount":97},[],{"trials":447,"activeCount":93,"soonestReadout":44},[448],{"nctId":42,"briefTitle":43,"status":107,"phases":449,"primaryCompletion":44,"completion":427,"start":428,"enrollment":429,"conditions":450,"interventions":451},[86,87],[431],[45,433],{"trials":453,"activeCount":97},[],{"trials":455,"activeCount":97},[],{"trials":457,"activeCount":97},[],{"intervention":459,"totalTrials":93,"cells":460},"ITNK cell therapy",{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":477,"PHASE4":479,"NA":481},{"trials":462,"activeCount":97},[],{"trials":464,"activeCount":97},[],{"trials":466,"activeCount":93,"soonestReadout":471},[467],{"nctId":468,"briefTitle":469,"status":107,"phases":470,"primaryCompletion":471,"completion":211,"start":212,"enrollment":472,"conditions":473,"interventions":476},"NCT03882840","Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I",[86,87],"2028-01-01",60,[474,475],"Anti-cancer Cell Immunotherapy","T Cell and NK Cell",[459],{"trials":478,"activeCount":97},[],{"trials":480,"activeCount":97},[],{"trials":482,"activeCount":97},[],{"intervention":138,"totalTrials":93,"cells":484},{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":495,"PHASE4":497,"NA":499},{"trials":486,"activeCount":97},[],{"trials":488,"activeCount":97},[],{"trials":490,"activeCount":93,"soonestReadout":132},[491],{"nctId":129,"briefTitle":130,"status":107,"phases":492,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":493,"interventions":494},[87],[14],[138,60],{"trials":496,"activeCount":97},[],{"trials":498,"activeCount":97},[],{"trials":500,"activeCount":97},[],{"intervention":502,"totalTrials":93,"cells":503},"LEN+SIN+DEB-TACE+HAIC",{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":519,"PHASE4":521,"NA":523},{"trials":505,"activeCount":97},[],{"trials":507,"activeCount":97},[],{"trials":509,"activeCount":93,"soonestReadout":133},[510],{"nctId":511,"briefTitle":512,"status":107,"phases":513,"primaryCompletion":133,"completion":514,"start":134,"enrollment":515,"conditions":516,"interventions":517},"NCT06904183","Lenvatinib, Sintilimab, and DEB-TACE With\u002FWithout HAIC for HCC >7 cm With PVTT",[87],"2030-03-31",320,[14],[502,518],"LEN+SIN+DEB-TACE",{"trials":520,"activeCount":97},[],{"trials":522,"activeCount":97},[],{"trials":524,"activeCount":97},[],{"intervention":518,"totalTrials":93,"cells":526},{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":528,"activeCount":97},[],{"trials":530,"activeCount":97},[],{"trials":532,"activeCount":93,"soonestReadout":133},[533],{"nctId":511,"briefTitle":512,"status":107,"phases":534,"primaryCompletion":133,"completion":514,"start":134,"enrollment":515,"conditions":535,"interventions":536},[87],[14],[502,518],{"trials":538,"activeCount":97},[],{"trials":540,"activeCount":97},[],{"trials":542,"activeCount":97},[],{"intervention":83,"totalTrials":93,"cells":544},{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":559,"PHASE4":561,"NA":563},{"trials":546,"activeCount":97},[],{"trials":548,"activeCount":97},[],{"trials":550,"activeCount":93,"soonestReadout":78},[551],{"nctId":81,"briefTitle":82,"status":107,"phases":552,"primaryCompletion":78,"completion":553,"start":554,"enrollment":555,"conditions":556,"interventions":557},[87],"2028-04-30","2024-05-01",130,[14],[83,558],"DEB-TACE",{"trials":560,"activeCount":97},[],{"trials":562,"activeCount":97},[],{"trials":564,"activeCount":97},[],{"intervention":558,"totalTrials":93,"cells":566},{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":577,"PHASE4":579,"NA":581},{"trials":568,"activeCount":97},[],{"trials":570,"activeCount":97},[],{"trials":572,"activeCount":93,"soonestReadout":78},[573],{"nctId":81,"briefTitle":82,"status":107,"phases":574,"primaryCompletion":78,"completion":553,"start":554,"enrollment":555,"conditions":575,"interventions":576},[87],[14],[83,558],{"trials":578,"activeCount":97},[],{"trials":580,"activeCount":97},[],{"trials":582,"activeCount":97},[],{"intervention":584,"totalTrials":93,"cells":585},"Sin-Bev-SIRT",{"EARLY_PHASE1":586,"PHASE1":588,"PHASE2":590,"PHASE3":599,"PHASE4":601,"NA":603},{"trials":587,"activeCount":97},[],{"trials":589,"activeCount":97},[],{"trials":591,"activeCount":93,"soonestReadout":78},[592],{"nctId":593,"briefTitle":594,"status":107,"phases":595,"primaryCompletion":78,"completion":78,"start":554,"enrollment":596,"conditions":597,"interventions":598},"NCT06397222","Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC",[87],23,[14],[584],{"trials":600,"activeCount":97},[],{"trials":602,"activeCount":97},[],{"trials":604,"activeCount":97},[],{"intervention":606,"totalTrials":93,"cells":607},"Skin drug prepared with exome originated from stem cell",{"EARLY_PHASE1":608,"PHASE1":610,"PHASE2":612,"PHASE3":624,"PHASE4":626,"NA":628},{"trials":609,"activeCount":97},[],{"trials":611,"activeCount":97},[],{"trials":613,"activeCount":93,"soonestReadout":375},[614],{"nctId":615,"briefTitle":616,"status":617,"phases":618,"primaryCompletion":375,"completion":376,"start":324,"enrollment":619,"conditions":620,"interventions":623},"NCT06480123","Stem Cell Derived Exome for Treatment of Diabetic Foot","NOT_YET_RECRUITING",[86,87],50,[621,622],"Diabetic Foot","Stem Cell",[606],{"trials":625,"activeCount":97},[],{"trials":627,"activeCount":97},[],{"trials":629,"activeCount":97},[],{"intervention":40,"totalTrials":93,"cells":631},{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":645,"PHASE4":647,"NA":649},{"trials":633,"activeCount":97},[],{"trials":635,"activeCount":97},[],{"trials":637,"activeCount":93,"soonestReadout":39},[638],{"nctId":37,"briefTitle":38,"status":107,"phases":639,"primaryCompletion":39,"completion":640,"start":641,"enrollment":642,"conditions":643,"interventions":644},[87],"2026-08-09","2023-08-10",30,[22],[40],{"trials":646,"activeCount":97},[],{"trials":648,"activeCount":97},[],{"trials":650,"activeCount":97},[],{"intervention":652,"totalTrials":93,"cells":653},"Injection of drug-eluting microspheres with multiple drugs into solid tumors",{"EARLY_PHASE1":654,"PHASE1":656,"PHASE2":658,"PHASE3":670,"PHASE4":672,"NA":674},{"trials":655,"activeCount":97},[],{"trials":657,"activeCount":97},[],{"trials":659,"activeCount":93,"soonestReadout":664},[660],{"nctId":661,"briefTitle":662,"status":107,"phases":663,"primaryCompletion":664,"completion":665,"start":666,"enrollment":667,"conditions":668,"interventions":669},"NCT04770207","Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs",[87],"2029-11-01","2035-11-01","2020-11-01",100,[22,17],[652],{"trials":671,"activeCount":97},[],{"trials":673,"activeCount":97},[],{"trials":675,"activeCount":97},[],{"intervention":677,"totalTrials":93,"cells":678},"Combination of three inhibitors Trametinib, Everolimus and Lenvatinib",{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":693,"PHASE4":695,"NA":697},{"trials":680,"activeCount":97},[],{"trials":682,"activeCount":97},[],{"trials":684,"activeCount":93,"soonestReadout":210},[685],{"nctId":686,"briefTitle":687,"status":107,"phases":688,"primaryCompletion":210,"completion":689,"start":690,"enrollment":667,"conditions":691,"interventions":692},"NCT04803318","Trametinib Combined With Everolimus and Lenvatinib for Recurrent\u002FRefractory Advanced Solid Tumors",[87],"2037-01-01","2021-01-01",[17,22],[677],{"trials":694,"activeCount":97},[],{"trials":696,"activeCount":97},[],{"trials":698,"activeCount":97},[],{"intervention":700,"totalTrials":93,"cells":701},"ipilimumab +pembrolizumab +durvalumab",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":722,"PHASE4":724,"NA":726},{"trials":703,"activeCount":97},[],{"trials":705,"activeCount":97},[],{"trials":707,"activeCount":93,"soonestReadout":712},[708],{"nctId":709,"briefTitle":710,"status":107,"phases":711,"primaryCompletion":712,"completion":713,"start":714,"enrollment":667,"conditions":715,"interventions":721},"NCT05187338","Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors",[86,87],"2029-10-30","2035-10-30","2021-11-01",[20,25,716,28,717,243,31,718,246,719,720],"Colorectal Cancer","Ovary Cancer","Gastric Cancer","Esophageal Cancer","Sarcoma",[700],{"trials":723,"activeCount":97},[],{"trials":725,"activeCount":97},[],{"trials":727,"activeCount":97},[],{"intervention":729,"totalTrials":93,"cells":730},"DC cell Vaccine",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":743,"PHASE3":745,"PHASE4":747,"NA":749},{"trials":732,"activeCount":97},[],{"trials":734,"activeCount":93,"soonestReadout":364},[735],{"nctId":736,"briefTitle":737,"status":107,"phases":738,"primaryCompletion":364,"completion":365,"start":739,"enrollment":472,"conditions":740,"interventions":742},"NCT06477614","Anti-cancer DC Cell Vaccination to Treat Solid Tumors",[86],"2024-06-05",[17,741],"DC",[729],{"trials":744,"activeCount":97},[],{"trials":746,"activeCount":97},[],{"trials":748,"activeCount":97},[],{"trials":750,"activeCount":97},[],{"intervention":752,"totalTrials":93,"cells":753},"Cell therapy for solid tumors",{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":769,"PHASE3":771,"PHASE4":773,"NA":775},{"trials":755,"activeCount":97},[],{"trials":757,"activeCount":93,"soonestReadout":762},[758],{"nctId":759,"briefTitle":760,"status":107,"phases":761,"primaryCompletion":762,"completion":763,"start":764,"enrollment":642,"conditions":765,"interventions":768},"NCT06196294","GPC3\u002FMesothelin-CAR-γδT Cells Against Cancers",[86],"2030-11-30","2036-12-30","2024-05-10",[28,20,25,766,767,17],"Mesothelioma","CAR-T Cell Therapy",[752],{"trials":770,"activeCount":97},[],{"trials":772,"activeCount":97},[],{"trials":774,"activeCount":97},[],{"trials":776,"activeCount":97},[],{"intervention":778,"totalTrials":93,"cells":779},"CpG-ODN",{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":794,"PHASE3":796,"PHASE4":798,"NA":800},{"trials":781,"activeCount":97},[],{"trials":783,"activeCount":93,"soonestReadout":788},[784],{"nctId":785,"briefTitle":786,"status":107,"phases":787,"primaryCompletion":788,"completion":789,"start":790,"enrollment":619,"conditions":791,"interventions":793},"NCT04952272","Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors",[86],"2029-06-30","2036-06-30","2021-03-01",[20,22,792],"Solid Tumor",[778],{"trials":795,"activeCount":97},[],{"trials":797,"activeCount":97},[],{"trials":799,"activeCount":97},[],{"trials":801,"activeCount":97},[],{"intervention":55,"totalTrials":93,"cells":803},{"EARLY_PHASE1":804,"PHASE1":806,"PHASE2":817,"PHASE3":819,"PHASE4":821,"NA":823},{"trials":805,"activeCount":97},[],{"trials":807,"activeCount":93,"soonestReadout":54},[808],{"nctId":52,"briefTitle":53,"status":107,"phases":809,"primaryCompletion":54,"completion":810,"start":811,"enrollment":642,"conditions":812,"interventions":816},[86],"2036-08-01","2017-07-01",[20,813,814,815],"Cancer","Immunotherapy","CAR-T Cell",[55],{"trials":818,"activeCount":97},[],{"trials":820,"activeCount":97},[],{"trials":822,"activeCount":97},[],{"trials":824,"activeCount":97},[],{"intervention":826,"totalTrials":93,"cells":827},"Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells",{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":845,"PHASE3":847,"PHASE4":849,"NA":851},{"trials":829,"activeCount":97},[],{"trials":831,"activeCount":93,"soonestReadout":836},[832],{"nctId":833,"briefTitle":834,"status":107,"phases":835,"primaryCompletion":836,"completion":837,"start":838,"enrollment":213,"conditions":839,"interventions":844},"NCT05410717","CLDN6\u002FGPC3\u002FMesothelin\u002FAXL-CAR-NK Cell Therapy for Advanced Solid Tumors",[86],"2030-06-01","2036-05-31","2022-06-01",[840,841,842,843],"Stage IV Ovarian Cancer","Testis Cancer, Refractory","Endometrial Cancer Recurrent","CAR NK",[826],{"trials":846,"activeCount":97},[],{"trials":848,"activeCount":97},[],{"trials":850,"activeCount":97},[],{"trials":852,"activeCount":97},[],{"intervention":854,"totalTrials":93,"cells":855},"Neoantigen Polypeptide Vaccine",{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":869,"PHASE3":871,"PHASE4":873,"NA":875},{"trials":857,"activeCount":97},[],{"trials":859,"activeCount":93,"soonestReadout":864},[860],{"nctId":861,"briefTitle":862,"status":107,"phases":863,"primaryCompletion":864,"completion":865,"start":866,"enrollment":642,"conditions":867,"interventions":868},"NCT06195293","Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors",[86],"2029-12-30","2037-12-30","2024-06-04",[17],[854],{"trials":870,"activeCount":97},[],{"trials":872,"activeCount":97},[],{"trials":874,"activeCount":97},[],{"trials":876,"activeCount":97},[],{"intervention":878,"totalTrials":93,"cells":879},"GPC3 and\u002For TGFβ targeting CAR-T cells",{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":895,"PHASE3":897,"PHASE4":899,"NA":901},{"trials":881,"activeCount":97},[],{"trials":883,"activeCount":93,"soonestReadout":888},[884],{"nctId":885,"briefTitle":886,"status":107,"phases":887,"primaryCompletion":888,"completion":810,"start":811,"enrollment":642,"conditions":889,"interventions":894},"NCT03198546","GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression",[86],"2029-08-01",[22,814,890,891,892,893],"CAR","GPC3 Gene Inactivation","T Cell","Squamous Cell Lung Cancer",[878],{"trials":896,"activeCount":97},[],{"trials":898,"activeCount":97},[],{"trials":900,"activeCount":97},[],{"trials":902,"activeCount":97},[],{"intervention":904,"totalTrials":93,"cells":905},"TCR-T cells",{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":918,"PHASE3":920,"PHASE4":922,"NA":924},{"trials":907,"activeCount":97},[],{"trials":909,"activeCount":93,"soonestReadout":864},[910],{"nctId":911,"briefTitle":912,"status":107,"phases":913,"primaryCompletion":864,"completion":763,"start":914,"enrollment":642,"conditions":915,"interventions":917},"NCT03778814","TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors",[86],"2018-12-01",[916,17],"Nonsmall Cell Lung Cancer",[904],{"trials":919,"activeCount":97},[],{"trials":921,"activeCount":97},[],{"trials":923,"activeCount":97},[],{"trials":925,"activeCount":97},[],{"intervention":927,"totalTrials":93,"cells":928},"CAR-T cells",{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":943,"PHASE3":945,"PHASE4":947,"NA":949},{"trials":930,"activeCount":97},[],{"trials":932,"activeCount":93,"soonestReadout":937},[933],{"nctId":934,"briefTitle":935,"status":107,"phases":936,"primaryCompletion":937,"completion":938,"start":939,"enrollment":642,"conditions":940,"interventions":942},"NCT05779917","Mesothelin\u002FGPC3\u002FGUCY2C-CAR-T Cells Against Cancers",[86],"2029-03-10","2036-03-10","2023-03-10",[28,767,941,17],"Mesothelin",[927],{"trials":944,"activeCount":97},[],{"trials":946,"activeCount":97},[],{"trials":948,"activeCount":97},[],{"trials":950,"activeCount":97},[],{"intervention":952,"totalTrials":93,"cells":953},"TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2\u002F6, ROR1, GD1, or B7-H3",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":969,"PHASE3":971,"PHASE4":973,"NA":975},{"trials":955,"activeCount":97},[],{"trials":957,"activeCount":93,"soonestReadout":962},[958],{"nctId":959,"briefTitle":960,"status":107,"phases":961,"primaryCompletion":962,"completion":211,"start":690,"enrollment":963,"conditions":964,"interventions":968},"NCT04842812","Engineered TILs\u002FCAR-TILs to Treat Advanced Solid Tumors",[86],"2029-12-31",40,[25,20,31,245,965,17,966,967],"Brain Tumor","PD1","CTLA4",[952],{"trials":970,"activeCount":97},[],{"trials":972,"activeCount":97},[],{"trials":974,"activeCount":97},[],{"trials":976,"activeCount":97},[],{"intervention":978,"totalTrials":93,"cells":979},"Neoantigen mRNA Vaccine",{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":992,"PHASE3":994,"PHASE4":996,"NA":998},{"trials":981,"activeCount":97},[],{"trials":983,"activeCount":93,"soonestReadout":988},[984],{"nctId":985,"briefTitle":986,"status":107,"phases":987,"primaryCompletion":988,"completion":865,"start":989,"enrollment":642,"conditions":990,"interventions":991},"NCT06195384","Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors",[86],"2027-12-30","2024-05-08",[17],[978],{"trials":993,"activeCount":97},[],{"trials":995,"activeCount":97},[],{"trials":997,"activeCount":97},[],{"trials":999,"activeCount":97},[],{"intervention":1001,"totalTrials":93,"cells":1002},"EGFR\u002FB7H3 CAR-T",{"EARLY_PHASE1":1003,"PHASE1":1016,"PHASE2":1018,"PHASE3":1020,"PHASE4":1022,"NA":1024},{"trials":1004,"activeCount":93,"soonestReadout":1009},[1005],{"nctId":1006,"briefTitle":1007,"status":107,"phases":1008,"primaryCompletion":1009,"completion":1010,"start":1011,"enrollment":642,"conditions":1012,"interventions":1015},"NCT05341492","EGFR\u002FB7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer",[85],"2030-05-01","2035-05-01","2022-05-01",[1013,1014],"EGFR\u002F B7H3-positive Advanced Lung Cancer","EGFR\u002F B7H3-positive Advanced Triple-negative Breast Cancer",[1001],{"trials":1017,"activeCount":97},[],{"trials":1019,"activeCount":97},[],{"trials":1021,"activeCount":97},[],{"trials":1023,"activeCount":97},[],{"trials":1025,"activeCount":97},[],{"intervention":1027,"totalTrials":93,"cells":1028},"CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells",{"EARLY_PHASE1":1029,"PHASE1":1040,"PHASE2":1042,"PHASE3":1044,"PHASE4":1046,"NA":1048},{"trials":1030,"activeCount":93,"soonestReadout":664},[1031],{"nctId":1032,"briefTitle":1033,"status":107,"phases":1034,"primaryCompletion":664,"completion":1035,"start":1036,"enrollment":9,"conditions":1037,"interventions":1039},"NCT05060796","Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC",[85],"2034-11-01","2019-09-01",[1038],"Non Small Cell Lung Cancer",[1027],{"trials":1041,"activeCount":97},[],{"trials":1043,"activeCount":97},[],{"trials":1045,"activeCount":97},[],{"trials":1047,"activeCount":97},[],{"trials":1049,"activeCount":97},[],{"intervention":69,"totalTrials":93,"cells":1051},{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1058,"PHASE4":1060,"NA":1062},{"trials":1053,"activeCount":97},[],{"trials":1055,"activeCount":97},[],{"trials":1057,"activeCount":97},[],{"trials":1059,"activeCount":97},[],{"trials":1061,"activeCount":97},[],{"trials":1063,"activeCount":93,"soonestReadout":68},[1064],{"nctId":66,"briefTitle":67,"status":107,"phases":1065,"primaryCompletion":68,"completion":664,"start":238,"enrollment":667,"conditions":1066,"interventions":1067},[90],[1038],[69],{"intervention":1069,"totalTrials":93,"cells":1070},"inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A\u002FC group.",{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1077,"PHASE4":1079,"NA":1081},{"trials":1072,"activeCount":97},[],{"trials":1074,"activeCount":97},[],{"trials":1076,"activeCount":97},[],{"trials":1078,"activeCount":97},[],{"trials":1080,"activeCount":97},[],{"trials":1082,"activeCount":93,"soonestReadout":1087},[1083],{"nctId":1084,"briefTitle":1085,"status":107,"phases":1086,"primaryCompletion":1087,"completion":1088,"start":811,"enrollment":1089,"conditions":1090,"interventions":1093},"NCT03192501","iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray",[],"2030-07-01","2039-07-01",250,[20,1091,1092,813],"Gene Abnormality","Gene Product Sequence Variation",[1069],{"intervention":79,"totalTrials":93,"cells":1095},{"EARLY_PHASE1":1096,"PHASE1":1098,"PHASE2":1100,"PHASE3":1102,"PHASE4":1104,"NA":1106},{"trials":1097,"activeCount":97},[],{"trials":1099,"activeCount":97},[],{"trials":1101,"activeCount":97},[],{"trials":1103,"activeCount":97},[],{"trials":1105,"activeCount":97},[],{"trials":1107,"activeCount":93,"soonestReadout":78},[1108],{"nctId":76,"briefTitle":77,"status":617,"phases":1109,"primaryCompletion":78,"completion":1110,"start":1111,"enrollment":667,"conditions":1112,"interventions":1115},[],"2027-10-30","2025-06-06",[1113,1114],"Epilepsy","Status Epilepticus",[79],{"intervention":1117,"totalTrials":93,"cells":1118},"Pregabalin",{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1125,"PHASE4":1138,"NA":1140},{"trials":1120,"activeCount":97},[],{"trials":1122,"activeCount":97},[],{"trials":1124,"activeCount":97},[],{"trials":1126,"activeCount":97},[1127],{"nctId":1128,"briefTitle":1129,"status":1130,"phases":1131,"primaryCompletion":1132,"completion":1132,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1136},"NCT03186443","Pregabalin Treatment and Prevention Post-herpetic Neuralgia","UNKNOWN",[88],"2017-10-01",342,[1135],"Herpetic Neuralgia",[1117,1137],"Gabapentin",{"trials":1139,"activeCount":97},[],{"trials":1141,"activeCount":97},[],{"intervention":1137,"totalTrials":93,"cells":1143},{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1148,"PHASE3":1150,"PHASE4":1156,"NA":1158},{"trials":1145,"activeCount":97},[],{"trials":1147,"activeCount":97},[],{"trials":1149,"activeCount":97},[],{"trials":1151,"activeCount":97},[1152],{"nctId":1128,"briefTitle":1129,"status":1130,"phases":1153,"primaryCompletion":1132,"completion":1132,"start":1132,"enrollment":1133,"conditions":1154,"interventions":1155},[88],[1135],[1117,1137],{"trials":1157,"activeCount":97},[],{"trials":1159,"activeCount":97},[],{"intervention":1161,"totalTrials":93,"cells":1162},"dTACE-HAIC protocol",{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1167,"PHASE3":1169,"PHASE4":1182,"NA":1184},{"trials":1164,"activeCount":97},[],{"trials":1166,"activeCount":97},[],{"trials":1168,"activeCount":97},[],{"trials":1170,"activeCount":97},[1171],{"nctId":1172,"briefTitle":1173,"status":1130,"phases":1174,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":1178,"interventions":1180},"NCT05263219","DEB-TACE+HAIC vs. HAIC for Large HCC",[88],"2026-02-09","2022-02-10",230,[1179],"Unresectable Hepatocellular Carcinoma",[1161,1181],"HAIC protocol",{"trials":1183,"activeCount":97},[],{"trials":1185,"activeCount":97},[],{"intervention":1181,"totalTrials":93,"cells":1187},{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1194,"PHASE4":1200,"NA":1202},{"trials":1189,"activeCount":97},[],{"trials":1191,"activeCount":97},[],{"trials":1193,"activeCount":97},[],{"trials":1195,"activeCount":97},[1196],{"nctId":1172,"briefTitle":1173,"status":1130,"phases":1197,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":1198,"interventions":1199},[88],[1179],[1161,1181],{"trials":1201,"activeCount":97},[],{"trials":1203,"activeCount":97},[],{"intervention":1205,"totalTrials":93,"cells":1206},"TACE combined with sorafenib and tislelizumab",{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1222,"PHASE4":1224,"NA":1226},{"trials":1208,"activeCount":97},[],{"trials":1210,"activeCount":97},[],{"trials":1212,"activeCount":97},[1213],{"nctId":1214,"briefTitle":1215,"status":1216,"phases":1217,"primaryCompletion":1218,"completion":1218,"start":1219,"enrollment":642,"conditions":1220,"interventions":1221},"NCT04599777","TACE Combined With Sorafenib and Tislelizumab for Advanced HCC","COMPLETED",[87],"2022-10-11","2020-10-01",[14],[1205],{"trials":1223,"activeCount":97},[],{"trials":1225,"activeCount":97},[],{"trials":1227,"activeCount":97},[],{"intervention":1229,"totalTrials":93,"cells":1230},"Carrilizumab, bevacizumab,capecitabine",{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1245,"PHASE4":1247,"NA":1249},{"trials":1232,"activeCount":97},[],{"trials":1234,"activeCount":97},[],{"trials":1236,"activeCount":97},[1237],{"nctId":1238,"briefTitle":1239,"status":1130,"phases":1240,"primaryCompletion":134,"completion":428,"start":168,"enrollment":1241,"conditions":1242,"interventions":1244},"NCT05965154","Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma",[87],22,[1243],"Head and Neck Squamous Cell Carcinoma",[1229],{"trials":1246,"activeCount":97},[],{"trials":1248,"activeCount":97},[],{"trials":1250,"activeCount":97},[],{"intervention":1252,"totalTrials":93,"cells":1253},"Donafenib+sintilimab",{"EARLY_PHASE1":1254,"PHASE1":1256,"PHASE2":1258,"PHASE3":1269,"PHASE4":1271,"NA":1273},{"trials":1255,"activeCount":97},[],{"trials":1257,"activeCount":97},[],{"trials":1259,"activeCount":97},[1260],{"nctId":1261,"briefTitle":1262,"status":1216,"phases":1263,"primaryCompletion":1264,"completion":1265,"start":1266,"enrollment":642,"conditions":1267,"interventions":1268},"NCT05162352","Donafenib Plus Sintilimab for Advanced HCC",[87],"2022-10-28","2023-08-31","2021-12-04",[22],[1252],{"trials":1270,"activeCount":97},[],{"trials":1272,"activeCount":97},[],{"trials":1274,"activeCount":97},[],{"intervention":1276,"totalTrials":93,"cells":1277},"Regorafenib + sintilimab",{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1282,"PHASE3":1295,"PHASE4":1297,"NA":1299},{"trials":1279,"activeCount":97},[],{"trials":1281,"activeCount":97},[],{"trials":1283,"activeCount":97},[1284],{"nctId":1285,"briefTitle":1286,"status":1130,"phases":1287,"primaryCompletion":1288,"completion":1289,"start":1290,"enrollment":1291,"conditions":1292,"interventions":1293},"NCT04718909","Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC",[87],"2023-07-08","2023-12-31","2021-01-09",166,[14],[1276,1294],"Regorafenib",{"trials":1296,"activeCount":97},[],{"trials":1298,"activeCount":97},[],{"trials":1300,"activeCount":97},[],{"intervention":1294,"totalTrials":93,"cells":1302},{"EARLY_PHASE1":1303,"PHASE1":1305,"PHASE2":1307,"PHASE3":1313,"PHASE4":1315,"NA":1317},{"trials":1304,"activeCount":97},[],{"trials":1306,"activeCount":97},[],{"trials":1308,"activeCount":97},[1309],{"nctId":1285,"briefTitle":1286,"status":1130,"phases":1310,"primaryCompletion":1288,"completion":1289,"start":1290,"enrollment":1291,"conditions":1311,"interventions":1312},[87],[14],[1276,1294],{"trials":1314,"activeCount":97},[],{"trials":1316,"activeCount":97},[],{"trials":1318,"activeCount":97},[],{"intervention":1320,"totalTrials":93,"cells":1321},"Avatrombopag",{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1337,"PHASE4":1339,"NA":1341},{"trials":1323,"activeCount":97},[],{"trials":1325,"activeCount":97},[],{"trials":1327,"activeCount":97},[1328],{"nctId":1329,"briefTitle":1330,"status":1130,"phases":1331,"primaryCompletion":1332,"completion":1332,"start":1333,"enrollment":642,"conditions":1334,"interventions":1336},"NCT06001567","Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and\u002For HAIC",[87],"2024-08-13","2023-08-14",[1335,22],"Thrombocytopenia",[1320],{"trials":1338,"activeCount":97},[],{"trials":1340,"activeCount":97},[],{"trials":1342,"activeCount":97},[],{"intervention":1344,"totalTrials":93,"cells":1345},"Drugs and anti-CD19 CAR transduced T cells",{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1363,"PHASE4":1365,"NA":1367},{"trials":1347,"activeCount":97},[],{"trials":1349,"activeCount":97},[],{"trials":1351,"activeCount":97},[1352],{"nctId":1353,"briefTitle":1354,"status":1130,"phases":1355,"primaryCompletion":1356,"completion":1356,"start":1357,"enrollment":667,"conditions":1358,"interventions":1362},"NCT03191773","A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory \u002FRelapsed B Cell Malignancies",[86,87],"2020-12-31","2017-06-30",[1359,1360,1361],"Acute Lymphocytic Leukemia","Chronic Lymphocytic Leukemia","Lymphoma",[1344],{"trials":1364,"activeCount":97},[],{"trials":1366,"activeCount":97},[],{"trials":1368,"activeCount":97},[],{"intervention":1370,"totalTrials":93,"cells":1371},"TACE combined with lenvatinib and sintilimab",{"EARLY_PHASE1":1372,"PHASE1":1374,"PHASE2":1376,"PHASE3":1386,"PHASE4":1388,"NA":1390},{"trials":1373,"activeCount":97},[],{"trials":1375,"activeCount":97},[],{"trials":1377,"activeCount":97},[1378],{"nctId":1379,"briefTitle":1380,"status":1216,"phases":1381,"primaryCompletion":1382,"completion":1383,"start":1219,"enrollment":642,"conditions":1384,"interventions":1385},"NCT04599790","TACE Combined With Lenvatinib and Sintilimab for Advanced HCC",[87],"2021-11-29","2022-10-31",[14],[1370],{"trials":1387,"activeCount":97},[],{"trials":1389,"activeCount":97},[],{"trials":1391,"activeCount":97},[],{"intervention":1393,"totalTrials":93,"cells":1394},"Aribulin;carboplatin;bevacizumab",{"EARLY_PHASE1":1395,"PHASE1":1397,"PHASE2":1399,"PHASE3":1408,"PHASE4":1410,"NA":1412},{"trials":1396,"activeCount":97},[],{"trials":1398,"activeCount":97},[],{"trials":1400,"activeCount":97},[1401],{"nctId":1402,"briefTitle":1403,"status":1130,"phases":1404,"primaryCompletion":134,"completion":428,"start":168,"enrollment":1405,"conditions":1406,"interventions":1407},"NCT05965141","Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer",[86,87],38,[244],[1393],{"trials":1409,"activeCount":97},[],{"trials":1411,"activeCount":97},[],{"trials":1413,"activeCount":97},[],{"intervention":1415,"totalTrials":93,"cells":1416},"TACE combined with sintilimab and bevacizumab",{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1431,"PHASE3":1433,"PHASE4":1435,"NA":1437},{"trials":1418,"activeCount":97},[],{"trials":1420,"activeCount":97},[1421],{"nctId":1422,"briefTitle":1423,"status":1130,"phases":1424,"primaryCompletion":1425,"completion":1426,"start":1427,"enrollment":1428,"conditions":1429,"interventions":1430},"NCT04592029","TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC",[86],"2022-06-30","2022-12-31","2020-09-27",36,[14],[1415],{"trials":1432,"activeCount":97},[],{"trials":1434,"activeCount":97},[],{"trials":1436,"activeCount":97},[],{"trials":1438,"activeCount":97},[],{"intervention":1440,"totalTrials":93,"cells":1441},"Tirelizumab；Chemotherapy monotherapy",{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1453,"PHASE3":1455,"PHASE4":1457,"NA":1459},{"trials":1443,"activeCount":97},[],{"trials":1445,"activeCount":97},[1446],{"nctId":1447,"briefTitle":1448,"status":1130,"phases":1449,"primaryCompletion":134,"completion":428,"start":168,"enrollment":1450,"conditions":1451,"interventions":1452},"NCT05965102","Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer",[86],31,[402],[1440],{"trials":1454,"activeCount":97},[],{"trials":1456,"activeCount":97},[],{"trials":1458,"activeCount":97},[],{"trials":1460,"activeCount":97},[],{"intervention":1462,"totalTrials":93,"cells":1463},"Hematoporphyrin Injection actived by photodynamic therapy combined with Sonodynamic Therapy",{"EARLY_PHASE1":1464,"PHASE1":1466,"PHASE2":1468,"PHASE3":1470,"PHASE4":1472,"NA":1474},{"trials":1465,"activeCount":97},[],{"trials":1467,"activeCount":97},[],{"trials":1469,"activeCount":97},[],{"trials":1471,"activeCount":97},[],{"trials":1473,"activeCount":97},[],{"trials":1475,"activeCount":97},[1476],{"nctId":1477,"briefTitle":1478,"status":1130,"phases":1479,"primaryCompletion":1480,"completion":1480,"start":1481,"enrollment":18,"conditions":1482,"interventions":1484},"NCT05580328","An Exploratory Clinical Study of Photodynamic Therapy Combined With Sonodynamic Therapy in Cholangiocarcinoma",[90],"2024-10-01","2022-12-01",[1483],"Cholangiocarcinoma",[1462],{"intervention":1486,"totalTrials":93,"cells":1487},"Sugammadex",{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1494,"PHASE4":1496,"NA":1498},{"trials":1489,"activeCount":97},[],{"trials":1491,"activeCount":97},[],{"trials":1493,"activeCount":97},[],{"trials":1495,"activeCount":97},[],{"trials":1497,"activeCount":97},[],{"trials":1499,"activeCount":97},[1500],{"nctId":1501,"briefTitle":1502,"status":1216,"phases":1503,"primaryCompletion":1504,"completion":1504,"start":1505,"enrollment":1506,"conditions":1507,"interventions":1508},"NCT04944303","The Feasibility of Sugammadex for General Anesthesia in Patients Undergoing Kidney and Pancreas Transplantation Surgery",[90],"2021-04-21","2020-12-18",52,[34],[1486,1509],"Normal saline",{"intervention":1509,"totalTrials":93,"cells":1511},{"EARLY_PHASE1":1512,"PHASE1":1514,"PHASE2":1516,"PHASE3":1518,"PHASE4":1520,"NA":1522},{"trials":1513,"activeCount":97},[],{"trials":1515,"activeCount":97},[],{"trials":1517,"activeCount":97},[],{"trials":1519,"activeCount":97},[],{"trials":1521,"activeCount":97},[],{"trials":1523,"activeCount":97},[1524],{"nctId":1501,"briefTitle":1502,"status":1216,"phases":1525,"primaryCompletion":1504,"completion":1504,"start":1505,"enrollment":1506,"conditions":1526,"interventions":1527},[90],[34],[1486,1509],{"intervention":1529,"totalTrials":93,"cells":1530},"SIRT-L-P",{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1535,"PHASE3":1537,"PHASE4":1539,"NA":1541},{"trials":1532,"activeCount":97},[],{"trials":1534,"activeCount":97},[],{"trials":1536,"activeCount":97},[],{"trials":1538,"activeCount":97},[],{"trials":1540,"activeCount":97},[],{"trials":1542,"activeCount":97},[1543],{"nctId":1544,"briefTitle":1545,"status":1216,"phases":1546,"primaryCompletion":1547,"completion":1547,"start":838,"enrollment":1548,"conditions":1549,"interventions":1550},"NCT06916546","SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC",[],"2025-01-31",238,[14],[1529,1551],"TACE-L-P",{"intervention":1551,"totalTrials":93,"cells":1553},{"EARLY_PHASE1":1554,"PHASE1":1556,"PHASE2":1558,"PHASE3":1560,"PHASE4":1562,"NA":1564},{"trials":1555,"activeCount":97},[],{"trials":1557,"activeCount":97},[],{"trials":1559,"activeCount":97},[],{"trials":1561,"activeCount":97},[],{"trials":1563,"activeCount":97},[],{"trials":1565,"activeCount":97},[1566],{"nctId":1544,"briefTitle":1545,"status":1216,"phases":1567,"primaryCompletion":1547,"completion":1547,"start":838,"enrollment":1548,"conditions":1568,"interventions":1569},[],[14],[1529,1551]]